Tillotts Pharma AG – our exclusive licensing partner for European and Japanese rights to develop and commercialize the combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP), an orphan disease, and other gastrointestinal conditions. View press release.
NMTRC – the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) is a group of 18 universities and children’s hospitals headquartered at the Helen DeVos Children’s Hospital that offer a nationwide network of childhood cancer clinical trials.
NANT and the Children’s Hospital of LA – New Approaches to Neuroblastoma Therapy is a group of 15 Universities and Children’s Hospitals with strong research and treatment programs for neuroblastoma.
NCI/SWOG – the National Cancer Institute (NCI) and Southwest Oncology Group, an NCI-supported clinical trials group.
CEPiA Sanofi – our manufacturing partner – Within the Industrial Affairs Division of Sanofi, CEPiA is an organization fully dedicated to third party CMO activities.
TRAC – Translational Accelerator, LLC, a venture fund formed to invest in Arizona biotech companies, is the lead investor.
Former Biotech and Pharmaceutical executives – featuring Board level executives and commercialization experts.